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AbstrACt
Objective Ten Top Tips (10TT) is a primary care-led 
behavioural intervention which aims to help adults reduce 
and manage their weight by following 10 weight loss tips. 
The intervention promotes habit formation to encourage 
long-term behavioural changes. The aim of this study was to 
estimate the cost-effectiveness of 10TT in general practice 
from the perspective of the UK National Health Service.
Design An economic evaluation was conducted alongside 
an individually randomised controlled trial.
setting 14 general practitioner practices in England.
Participants All patients were aged ≥18 years, with 
body mass index ≥30 kg/m2. A total of 537 patients were 
recruited; 270 received the usual care offered by their 
practices and 267 received the 10TT intervention.
Outcomes measures Health service use and quality-
adjusted life years (QALYs) were measured over 2 years. 
Analysis was conducted in terms of incremental net 
monetary benefits (NMBs), using non-parametric 
bootstrapping and multiple imputation.
results Over a 2-year time horizon, the mean costs and 
QALYs per patient in the 10TT group were £1889 (95% CI 
£1522 to £2566) and 1.51 (95% CI 1.44 to 1.58). The mean 
costs and QALYs for usual care were £1925 (95% CI £1599 
to £2251) and 1.51 (95% CI 1.45 to 1.57), respectively. This 
generated a mean cost difference of −£36 (95% CI −£512 to 
£441) and a mean QALY difference of 0.001 (95% CI −0.080 
to 0.082). The incremental NMB for 10TT versus usual 
care was £49 (95% CI −£1709 to £1800) at a maximum 
willingness to pay for a QALY of £20 000. 10TT had a 52% 
probability of being cost-effective at this threshold.
Conclusions Costs and QALYs for 10TT were not 
significantly different from usual care and therefore 10TT 
is as cost-effective as usual care. There was no evidence 
to recommend nor advice against offering 10TT to obese 
patients in general practices based on cost-effectiveness 
considerations.
trial registration number ISRCTN16347068; Post-
results.
IntrODuCtIOn
The worldwide prevalence of obesity nearly 
doubled between 1980 and 2008. Based on 
recent estimates in the European Union, 
overweight affects 30%–70% and obesity 
affects 10%–30% of adults.1 In the UK 
23.9% of women aged 18 years and over are 
obese—the highest proportion in Europe. 
The proportion of UK men who are obese 
is 22.1%, the second highest proportion in 
Europe behind Malta (24.7%).2 
Health risks associated with obesity 
range from heart disease, stroke and type 2 
diabetes, to all cancers, gall bladder disease 
and mortality.3 It is estimated that health 
problems associated with being overweight or 
obese cost the National Health Service (NHS) 
in England more than £5 billion every year.4
Non-surgical interventions for weight loss 
are available and include dietary advice, 
physical activity and behaviour modifica-
tion. These can be accessed mainly through 
primary care. Despite considerable invest-
ment in such interventions, there is limited 
evidence about their cost-effectiveness.5–9
Ten Top Tips (10TT) was a simple leaf-
let-based intervention for patients in primary 
strengths and limitations of this study
 ► The analysis is based on a large multicentre ran-
domised trial with detailed information on resource 
use and utility values for a median follow-up period 
of 2 years.
 ► Individual data on standard weight-loss interven-
tions received by the participant were not recorded.
 ► The analysis took a UK National Health Service 
(NHS)/personal social service perspective, but a 
wider perspective (eg, societal) could have been 
taken, including costs to patients and families.
 ► The time horizon was 2 years.
 ► Missing NHS resource use and utility data were ac-
counted for using multiple imputation.
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care designed to help with weight loss. The underpinning 
theory behind 10TT was habit formation. Psychological 
research shows that repetition of a simple action in a 
consistent context leads, through associative learning, 
to the action being activated on subsequent exposure 
to those contextual cues.10 A small pilot trial consisting 
of 100 people showed that those who received the 10TT 
leaflet lost significantly more weight than those who 
did not receive it.11 Although the absolute weight loss 
was modest, the intervention had the potential to be 
disseminated at minimal cost to large numbers simply by 
making the leaflet available. In response to this a large 
randomised trial was undertaken. Participants were given 
a leaflet, which provided weight loss tips based on scien-
tific evidence on how to turn the tips into healthy habits, 
during a 30 min appointment with a practice nurse. 
The 10 healthy tips included keeping to meal routines, 
reduced fat intake, walking off weight, packing a healthy 
snack, looking at food labels, taking caution with portion 
size, standing up, thinking about drinks, focusing on food 
and not forgetting ‘five a day’. The ‘five a day’ campaign 
is based on the recommendation from the WHO encour-
aging consumption of at least 400 g of fruits and vegeta-
bles a day to lower the risk of serious health problems, 
such as heart disease, stroke and some cancers.12 Partic-
ipants were asked to record their progress in a logbook. 
Using routinely collected data from primary care prac-
tices, the aim of the present study was to analyse the cost 
and cost-effectiveness of 10TT.
MethODs
trial background
The 10TT trial was a two-arm, individually randomised, 
controlled trial in which 537 obese men and women were 
enrolled.13 Practices across England (n=14) were recruited 
through the Medical Research Council General Practice 
Research Framework. They were located in Wellingbor-
ough, Southampton, Bradford-on-Avon, Bromsgrove, 
Frome, Guisborough, Glastonbury, Ivybridge, Dunstable, 
Liskeard, Ledbury, New Mills and London. The majority 
were located in Southern England (n=9), with three 
located in the Midlands and two in the North. Recruitment 
occurred between August 2010 and October 2011. Partic-
ipants were randomly assigned to 10TT (n=267) or usual 
care (n=270), and followed for up to 2 years. The primary 
outcome was weight loss at 3 months. The secondary 
outcomes included body mass index (BMI), waist circum-
ference, the number of people achieving a 5% reduction 
in weight, clinical markers for potential comorbidities 
(blood pressure, total cholesterol/low-density lipopro-
tein and blood glucose) and maintenance of weight loss 
over 24 months. At 3 months participants in the 10TT 
group lost significantly more weight than those receiving 
usual care (mean difference in weight change=−0.87 kg, 
95% CI −1.47 to −0.27, p=0.004). But this effect was not 
maintained at 24 months (mean difference in weight 
change=+0.75 kg, 95% CI −0.73 to 2.24). Weight loss in 
the usual care group was slow in the first 6 months, but 
it continued until 18 months, whereas the 10TT group 
experienced a greater weight loss in the first 6 months, 
but did not lose any additional weight after this point.
Patient and public involvement
There was patient representation on the trial steering 
group for 10TT; however, neither patients nor the public 
were involved in the economic analyses presented in this 
paper.
Overview of economic evaluation
We undertook a cost-utility analysis to compare the costs 
and outcomes associated with 10TT and usual care. The 
outcome measure was quality-adjusted life year (QALY), 
which combines the length of life and quality of life, 
and is consistent with the National Institute for Health 
and Care Excellence (NICE) recommendations.14 The 
primary outcomes were incremental costs and effects and 
the incremental net monetary benefit (NMB) of 10TT 
versus usual care. Costs were measured from an NHS 
and personal social services (PSS) perspective; since PSS 
costs were negligible, we focused on NHS costs. These 
were calculated in 2013/2014 UK£. The time horizon for 
costs and effects was 2 years, reflecting the trial follow-up 
period. Extrapolation beyond this time period was not 
undertaken because the within-trial analysis found no 
evidence of a significant difference in costs or outcomes at 
24 months; 2 years was therefore considered long enough 
to reflect all important differences in costs or outcomes 
between treatments. Costs and outcomes in the second 
year were discounted at 3.5%.14
resource use and costs
Resource use data were extracted from general practi-
tioner (GP) records for 2 years prior to randomisation 
and 2 years post randomisation on the number and type 
of contacts with the GP (surgery visit, home visit, phone 
call), practice nurse contacts (practice visit, home visit, 
phone call), dietitian visits, hospital outpatient visits, 
hospital inpatient stay, accident and emergency (A&E) 
visits, and outpatient services. Data on use of drugs 
included dose, type and frequency of administration. All 
resource use data were extracted by practice nurses at 
participating centres from patient records.
Unit costs were attached to each resource item. The 
cost per visit to primary care (GP surgery visit, GP home 
visit, GP phone call, practice nurse visit, nurse home visit, 
practice nurse phone call and dietitian visits) was taken 
from Personal Social Services Research Unit (PSSRU) 
estimates.15 The costs of inpatient episodes, outpatient 
visits and A&E visits were taken from the PSSRU and 
based on the NHS reference costs.16 They included costs 
of medical staff, equipment, consumables and diagnos-
tics. The weighted average cost of inpatient stays was 
calculated combining the cost of inpatient long and short 
stays. Drug costs were obtained from the British National 
Formulary.17
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The cost of the 10TT intervention included the 
following, valued using market prices: a logbook (£2.80 
per participant); time patients spent with the practice 
nurse to introduce the programme (£20 for a 30 min visit); 
wallet-sized food label guidance (£0.09) and a 10TT leaflet 
(£0.05). The total cost of 10TT was £22.94 per participant. 
The cost of the food label guidance was based on the total 
cost of printing (£1392) divided by the number of labels 
printed (15 000). Similarly, the cost of 10TT leaflets was 
based on the total cost of printing (£1540) divided by the 
number of leaflets printed (30 000).
All practices offered standard weight-loss interven-
tions as part of usual care. These consisted of a range 
of interventions including referrals to community 
programmes, gym prescription and referral to a dieti-
tian and/or psychologist, among others. While data were 
provided by practices on interventions typically offered 
to their patients, the uptake of these interventions was 
not recorded. In our base case, we made the conserva-
tive assumption (possibly biased against 10TT) that no 
patients received these interventions. In a sensitivity anal-
ysis, we included the costs of these interventions assuming 
each patient in the control group received the standard 
weight-loss intervention offered by the practice. Where 
single interventions were offered by a practice, these 
were costed accordingly, based on the average cost of 
participating in Weight Watchers (assumed to cost £78.22 
per patient18) or Slimming World (£72.62 per patient). 
Where multiple interventions were offered by a practice, 
these were costed based on the average cost of partici-
pating in the Size Down Programme at a cost of £93.48 
per patient.18
Unit costs (total expenditure incurred by the NHS for 
one visit) for each cost component are shown in table 1. 
These were multiplied by resource volume and summed 
across all cost components to obtain a total cost per 
patient.
utilities and QALYs
Health utilities were based on the EuroQol 5-dimen-
sion 3-level (EQ-5D-3L) descriptive system.19 20 This is 
a five-dimensional questionnaire (mobility, self-care, 
usual activities, pain and discomfort), with three levels 
in each dimension (severe problems, some problems, 
no problems). Each EQ-5D-3L state was converted into 
a single utility score based on valuations from the UK 
general population.21 Utility values of 1 represent full 
health, values of 0 are equivalent to death, and negative 
values represent states worse than death. The EQ-5D-3L 
questionnaire was completed at baseline, 3 months, 
6 months, 12 months, 18 months and 24 months. A 
utility profile was constructed for participants assuming 
a straight-line relation between their utility values at 
each measurement point. QALYs for every patient from 
baseline to 2 years were calculated as the area under the 
utility profile.
Dealing with missing data
There were missing data for NHS resource use and utility 
scores. Multivariate imputation by chained equations 
was used to impute missing data.22 23 The imputation 
method used an iterative Markov Chain Monte Carlo 
technique to simulate from the posterior predictive 
distribution of missing data.24 We generated 20 imputed 
data sets. We imputed missing data (% of missing data) 
for the following variables: weight (0.2%); BMI (0.2%); 
waist circumference (0.6%); EQ-5D-3L at baseline (5%), 
3 months (26%), 6 months (40%), 12 months (46%) 
and 24 months (46%); NHS visits (GP practice (28%), 
GP home (31%), GP phone calls (30%), practice nurse 
(27%), nurse home (31%), nurse phone calls (31%), 
extra nurse (30%), dietitian (31%), hospital inpatient 
stay (31%), outpatient clinic (30%), A&E visits (30%)); 
and other outpatient service visits (30%) (table 1). Age, 
sex and study centre were included in the imputation 
model as additional explanatory variables. Imputations 
were undertaken using the –mi impute mvn– command 
in Stata SE V.14.
statistical analysis
Two sample t-tests to test for differences in cost and QALYs 
between the two groups were carried out for complete 
data. A linear regression model was used to test for differ-
ences in mean resource use, costs, EQ-5D scores at each 
time point and QALYs25 26 using the imputed data. The 
incremental NMBs were calculated as the difference in 
mean QALYs per participant (Q) with 10TT (T) versus 
usual care (U) multiplied by the maximum willingness to 
pay for a QALY (R) minus the difference in mean cost per 
participant (C), that is, incremental NMB=(QT – QU)*R – 
(CT– CU). We used the cost-effectiveness threshold range 
recommended by NICE (£20 000–£30 00014) as the lower 
and upper limits of the maximum willingness to pay for 
a QALY (R). Negative incremental NMBs indicate that 
usual care is preferred on cost-effectiveness grounds, 
and positive incremental NMBs indicate that 10TT is 
preferred.27
We had initially adjusted for age, gender, practice and 
costs 2 years prior in the analysis for incremental costs. 
Similarly, we adjusted for age, gender, practice and base-
line utility values in the analysis for incremental QALYs. 
There were no differences between the two groups in 
terms of these factors (table 2) and therefore an unad-
justed model was used.
For each of the 20 imputed data sets, we ran 1000 
bootstrap replications using non-parametric bootstrap-
ping, resampling observations with replacement.28 The 
bootstrapped results were combined using the formula 
described by Briggs et al,23 to calculate the mean values 
for costs and utilities and the SEs around the imputed 
values. SEs were based on a normal distribution and used 
to calculate 95% CIs around point estimates.
The cost-effectiveness plane was used to illustrate the 
difference in costs and outcomes between the two groups. 
The probability that 10TT was cost-effective in comparison 
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with usual care at different values of the cost-effectiveness 
threshold was presented in the form of a cost-effectiveness 
acceptability curve (CEAC).29 The CEAC was based on the 
proportion of bootstrap replications across all 20 imputed 
data sets that were below the cost-effectiveness threshold, 
which was varied from £0 to £50 000.
Several deterministic sensitivity analyses were carried out 
to assess the uncertainty around key components of the 
analysis. An analysis was undertaken based on complete 
cases without any imputation. We varied cost components 
for primary and secondary care costs and drug costs. The 
total costs of each component were amended by ±10%. We 
also conducted an analysis including the cost of standard 
weight-loss interventions for the usual care group.
resuLts
baseline description
Table 3 illustrates the mean costs 2 years prior to the 
trial. The mean cost for the usual care group was £1848 
Table 1 Resource use, unit cost and mean cost per participant for primary and secondary care services postrandomisation
n
Usual care 10TT
Unit 
cost (£)
Usual 
care 10TT Incremental difference
 Mean (SD)
Median 
(IQR) Mean (SD)
Median 
(IQR)
Mean 
cost 
(£)
Mean 
cost 
(£)
Mean 
(£) (95% CI)
No imputation for missing values
GP surgery visit 204 9.4 (8.4) 7 (7.00) 9.7 (9.5) 7 (9.00) 45 417 425 8 (−72 to 89)
GP home visit 196 0.1 (0.8) 0 (0.00) 0.0 (0.1) 0 (0.00) 292 37 9 −27 (−61 to 7)
GP phone 199 1.3 (3.0) 0 (1.00) 1.3 (3.0) 0 (1.00) 27 34 34 0 (−16 to 16)
GP practice nurse 206 6.9 (8.4) 4 (6.00) 6.8 (9.5) 4 (6.50) 40 274 268 −6 (−77 to 64)
Nurse home visit 195 0.1 (1.1) 0 (0.00) 0.0 (0.1) 0 (0.00) 70 5 1 −4 (−16 to 7)
GP practice nurse phone 197 0.5 (2.3) 0 (0.00) 0.4 (1.2) 0 (0.00) 10 5 4 −1 (−5 to 2)
Dietitian 195 0.1 (0.5) 0 (0.00) 0.1 (0.8) 0 (0.00) 35 4 4 0 (−4 to 4)
Additional nurse visit 197 1.1 (3.1) 0 (1.00) 1.6 (2.6) 0 (1.00) 4 45 44 0 (−23 to 22)
Inpatient admission 196 0.2 (0.7) 0 (0.00) 0.2 (0.7) 0 (0.00) 1713 372 387 14 (−220 to 249)
Outpatient clinic 200 2.2 (3.5) 1 (3.00) 2.1 (3.3) 1 (3.00) 135 288 269 −20 (−110 to 70)
Accident and emergency 
visit
199 0.4 (1.2) 0 (0.00) 0.4 (0.9) 0 (1.00) 177 65 67 2 (−36 to 39)
Other outpatient services 194 1.0 (1.8) 0 (1.00) 1.0 (2.3) 0 (1.00) 135 124 129 5 (−48 to 58)
Missing values imputed*   SE   SE
GP surgery visit 270 9.4 (0.6) 9 9.4 (0.7) 9 45 419 420 1 (−79 to 81)
GP home visit 270 0.1 (0.5) 0 0.0 (0.2) 0 292 36 13 −23 (−58 to 12)
GP phone 270 1.3 (0.2) 1 1.3 (0.2) 1 27 35 33 −2 (−19 to 14)
GP practice nurse 270 6.9 (0.6) 6 6.6 (0.7) 6 40 274 266 −9 (−75 to 57)
Nurse home visit 270 0.1 (1.0) 0 0.0 (0.1) 0 70 6 2 −4 (−16 to 7)
GP practice nurse phone 270 0.5 (0.6) 0 0.4 (0.1) 0 10 5 4 −1 (−5 to 2)
Dietitian 270 0.1 (0.0) 0 0.1 (0.6) 0 35 4 4 0 (−4 to 4)
Additional nurse visit 270 1.2 (0.2) 1 1.8 (0.2) 0 4 46 47 0 (−23 to 23)
Inpatient admission 270 0.2 (0.1) 0 0.2 (0.1) 0 1713 373 379 6 (−238 to 251)
Outpatient clinic 270 2.1 (0.3) 2 2.0 (0.2) 0 135 287 266 −22 (−106 to 63)
Accident and emergency 
visit
270 0.4 (0.9) 0 0.4 (0.7) 0 177 67 69 2 (−38 to 42)
Other outpatient services 270 1 (0.1) 1 1 (0.2) 0 135 122 129 6 (−52 to 65)
Weight-loss interventions
10TT – – – – 23 – – 
Weight Watchers – – – 78 – – 
Slimming World – – – – 93 – – 
Size Down Programme – – –  – 73 – – 
 Costs are in 2013/2014 UK£.
SD for non-imputed data. SE for imputed data.
*Missing values imputed using multiple imputation with 20 imputed data sets (see text).
10TT, Ten Top Tips; GP, general practitioner. 
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(95% CI 1615 to 2082) and £2052 (95% CI 1756 to 
2349) for the 10TT group. Baseline characteristics—age, 
gender, weight, BMI, blood pressure and cholesterol—
did not differ between groups.13
base case
Table 1 shows the mean imputed resource use by treat-
ment group. The intervention and control groups had 
the same mean GP practice visits per participant over the 
2-year period (9.4 vs 9.4), as well as similar GP home visits 
(0.0 vs 0.1), GP phone contacts (1.3 vs 1.3), nurse prac-
tice visits (6.6 vs 6.9), nurse home visits (0.0 vs 0.1), inpa-
tient episodes (0.2 vs 0.2), outpatient clinic visits (2.0 vs 
2.1) and A&E visits (0.4 vs 0.4). There was no statistically 
significant difference between groups for any category of 
health service resource use.
Table 3 shows the total cost per participant in each 
group. The non-parametric bootstrapping including 
imputed resource use produced a mean total cost per 
participant in the intervention group of £1889 (95% CI 
£1522 to £2566), compared with £1925 (95% CI £1599 to 
£2251) in the control group. The mean difference in cost 
between 10TT and control group was −£36 (95% CI −£512 
to £441), which was not statistically significant (p=0.88).
Undertaking non-parametric bootstrapping after 
multiple imputation produced 1.51 (95% CI 1.44 to 1.58) 
QALYs in the intervention group and 1.51 (95% CI 1.45 
to 1.57) in the control group, generating a mean differ-
ence in QALYs of 0.001 (95% CI −0.080 to 0.082) (p=0.93) 
(tables 4 and 5), which was not statistically significant. 
Hence, patients receiving 10TT accrued non-significantly 
lower costs, and the difference in QALYs between the 
groups was very small and non-significant.
The incremental NMB for 10TT versus usual care was 
£49 (95% CI −£1709 to £1800) at a maximum willingness 
to pay for a QALY of £20 000 and £55 (95% CI −£2489 to 
£2583) at a maximum willingness to pay for a QALY of 
£30 000 (table 4).
Of the 20 000 bootstrap replications produced under 
base case assumptions, 24% fell into the south-west quad-
rant of the cost-effectiveness plane (10TT was less costly 
Table 3 Cost description 2 years prior and post randomisation
Usual care 10TT
Incremental 
difference
n Mean SD n Mean SD Mean (£) (95% CI)
Costs 2 years prior
  Cost of primary and secondary care contacts 270 1516 1694 267 1735 2186 219 (−112 to 550)
  Drugs costs 270 332 748 267 317 624 −15 (−132 to 102)
  Total cost 270 1848 1948 267 2052 2461 204 (−172 to 580)
Costs after randomisation (imputed)* SE SE
  Cost of primary and secondary care contacts 270 1675 150 267 1631 169 −45 (−477 to 387)
  Drugs costs 270 249 44 267 236 68 −13 (−172 to 146)
  Intervention costs – – – 267 23 – – 
  Total cost 270 1925 165 267 1889 186 −36 (−512 to 441)
SD for non-imputed data. SE for imputed data.
*Missing values imputed using multiple imputation with 20 imputed datasets (see text). 
10TT, Ten Top Tips.
Table 2 Demographics at baseline
Usual care 10TT
P values†n Mean* SD n Mean SD
Age 270 58 12.61 267 57 12.88 0.47
Male 95 35.2 – 89 33.3 – – 
Female 175 64.8 – 178 66.7 – – 
Prior costs 270 1848 1948 267 2052 2461 0.29
Weight (kg) 269 101 17.46 267 100 16.98 0.59
Body mass index 269 36.59 5.72 267 36.18 4.71 0.36
Baseline EQ-5D-3L 257 0.76 0.24 255 0.74 0.27 0.41
*Figures for sex based on the mean proportion (%) in each group.
†From independent t-test.
10TT, Ten Top Tips.
EQ-5D-3L, EuroQol 5-dimension 3-level descriptive system.
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and less effective than usual care); 20% fell into the north-
east quadrant (10TT was more costly and more effective 
than usual care); 25% fell into the north-west quadrant 
(10TT was more costly and less effective than usual care); 
and 31% fell into the south-east quadrant (10TT was less 
costly and more effective than usual care) (figure 1). 
The CEAC derived from figure 1 is illustrated in figure 2. 
Under base case assumptions, 10TT has a 52% probability 
of being cost-effective at a willingness to pay threshold 
of £20 000 and 52% at a willingness to pay threshold of 
£30 000 (table 4).
sensitivity analyses
Including the cost of the standard weight-loss interven-
tions (£87) in the usual care group, the mean costs per 
patient in the control group increased to £2012, which 
was higher than the mean cost in the intervention group 
(£1889). The mean incremental cost difference between 
groups was −£122 (95% CI −£598 to £353). The incre-
mental NMB for 10TT versus usual care was £140 (95% 
CI −£1666 to £1902) at a maximum willingness to pay for 
a QALY of £20 000 and £148 (95% CI −£2463 to £2693) 
at a maximum willingness to pay of £30 000. Increasing 
and decreasing costs by 10% did not affect the findings 
appreciably (table 4).
A complete case analysis was undertaken using 163 of 
537 participants with complete utility and cost data. The 
incremental NMB was −£889 (95% CI −£3993 to £2253) at 
a maximum willingness to pay for a QALY of £20 000 and 
−£1361 (95% CI −£5772 to £3052) at a maximum willing-
ness to pay for a QALY of £30 000.
DIsCussIOn
Our economic analysis of 10TT showed that this interven-
tion had similar costs and QALYs as usual care. Sensitivity 
analyses showed little uncertainty in this finding. On the 
one hand the findings mean there is no reason to prefer 
10TT or usual care on the basis of differences in quality 
of life or cost, or on cost-effectiveness grounds. On the 
other hand, this means that 10TT is as cost-effective as 
usual care.
We undertook a rapid review to compare our results 
with similar weight loss programmes. We found that 
commercial weight loss programmes were highly 
Table 5 Quality-adjusted life years (QALYs) per patient
Usual care 10TT Incremental difference
n Mean SD (95% CI) n Mean SD (95% CI) Mean (95% CI)
No imputation for 
missing values
Utility at 3 months 206 0.77 0.23 (0.74 to 0.80) 190 0.77 0.26 (0.73 to 0.80) 0.00 (−0.05 to 0.05)
Utility at 6 months 163 0.76 0.24 (0.72 to 0.80) 159 0.78 0.24 (0.74 to 0.82) 0.02 (−0.03 to 0.07)
Utility at 
12 months
151 0.77 0.24 (0.73 to 0.81) 138 0.74 0.27 (0.70 to 0.79) −0.03 (−0.09 to 0.03)
Utility at 
18 months
138 0.75 0.25 (0.71 to 0.79) 124 0.74 0.27 (0.69 to 0.79) −0.01 (−0.07 to 0.05)
Utility at 
24 months
157 0.76 0.25 (0.73 to 0.80) 131 0.76 0.26 (0.72 to 0.81) 0.00 (−0.06 to 0.06)
Discounted QALYs
(24 months)
92 1.52 0.40 (1.44 to 1.61) 73 1.47 0.47 (1.36 to 1.58) −0.05 (−0.18 to 0.08)
Missing values 
imputed*
SE SE
Utility at 3 months 270 0.77 0.016 (0.73 to 0.80) 267 0.77 0.017 (0.73 to 0.80) 0.00 (−0.05 to 0.05)
Utility at 6 months 270 0.76 0.016 (0.73 to 0.79) 267 0.78 0.018 (0.73 to 0.81) 0.01 (−0.03 to 0.06)
Utility at 
12 months
270 0.76 0.019 (0.73 to 0.80) 267 0.75 0.020 (0.71 to 0.80) −0.01 (−0.06 to 0.04)
Utility at 
18 months
270 0.76 0.019 (0.72 to 0.79) 267 0.75 0.020 (0.71 to 0.79) −0.01 (−0.05 to 0.04)
Utility at 
24 months
270 0.76 0.019 (0.72 to 0.79) 267 0.76 0.018 (0.72 to 0.79) 0.00 (−0.05 to 0.05)
Discounted QALYs
(24 months)
270 1.51 0.030 (1.45 to 1.57) 267 1.51 0.033 (1.44 to 1.58) 0.00 (−0.08 to 0.08)
Costs are in 2013/2014 UK£. CIs were based on non-parametric bootstrapping for observed data and imputed data.
SD for non-imputed data. SE for imputed data.
*Missing values imputed using multiple imputation with 20 imputed data sets (see text).
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prescribed among primary care providers, and these 
participants lost more weight than those in self-led educa-
tion programmes alone. Fuller et al7 reported the long-
term analysis of a 20 min GP consultation versus Weight 
Watchers and found Weight Watchers produced a cost 
saving of US$47 per patient and an incremental 0.03 
QALY gained per patient. Similarly, a recent evaluation 
in the UK of a primary care-led behavioural programme30 
looked at a brief advice and self-help materials (primary 
care-led programme) versus Weight Watchers over 
12 weeks and over 52 weeks. The authors concluded 
that Weight Watchers was more effective over 12 weeks 
(−4.75 kg) and 52 weeks (−6.76 kg) than brief advice and 
self-help material (−3.26 kg), at a cost of £159 per kilo-
gram lost. Additionally, a primary care-led programme 
Counterweight (a nurse-delivered patient education 
programme) showed that nurse-delivered education was 
less costly and more effective compared with no active 
intervention, producing a gain in QALYs (0.06 per partic-
ipant) and cost savings of £27 per participant.9
It is evident from existing literature that GPs play a 
crucial role in obesity prevention and weight manage-
ment and are gatekeepers to lifestyle weight manage-
ment programmes.31 While there is evidence to suggest 
GP prescribed commercial programmes and/or weight-
loss education is effective, further research is needed 
to explore the relationship between habit formation 
programmes such as 10TT and commercial programmes, 
with the aim to determine what the long-term cost savings 
and QALYs produced would potentially be over a long-
time horizon.
The main strength of our analysis is that it is based 
on a large multicentre randomised trial with detailed 
information on resource use and utility values for a 
median follow-up period of 2 years. There were several 
limitations to our study. While data were recorded in 
the trial on standard weight-loss interventions for obese 
patients at each practice, individual data on the uptake 
and prescribing of standard weight-loss interventions 
received by the participant were not recorded. This trial 
was also unblinded, which introduced the potential bias 
of GPs over prescribing standard weight-loss interven-
tions producing a healthy user bias effect. Under base 
case assumptions, excluding standard weight-loss inter-
ventions, the incremental NMB of 10TT versus usual care 
Figure 1 Cost-effectiveness plane, base case analysis assumptions. Based on 20 000 bootstrap replications, from 20 imputed 
data sets.
Figure 2 Cost-effectiveness acceptability curve showing 
the probability that Ten Top Tips is cost-effective versus usual 
care at different values of the maximum willingness to pay for 
a quality-adjusted life year (QALY) (base case assumptions).
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was not significantly different from zero, and this did not 
change when intervention costs in the control group were 
included. Hence, these costs did not make an appreciable 
difference to our conclusions. Second, the analysis took a 
UK NHS/PSS perspective. A wider perspective (eg, soci-
etal) could have been taken, including costs to patients 
and families. Third, the time horizon was limited to 2 years 
due to the lack of difference in costs (−£36, 95% CI −£512 
to £441, p value 0.88) and benefits (0.001, 95% CI −0.080 
to 0.082, p value 0.93) at 24 months between groups. 
The trial did not capture QALYs from weight loss post 
24 months. A longer follow-up period may have allowed 
for the detection of long-term health benefits produced 
as a consequence of avoiding obesity-related health 
conditions, such as diabetes and cardiovascular disease. 
However, at the time of this study little was known about 
the association between habit formation and weight loss. 
This study has identified the importance of longer term 
strategies for continued adherence of weight loss. With 
add-on approaches such as counselling and education 
on how to maintain weight loss for participants along-
side 10TT, it may be possible to maintain weight loss post 
2 years.
Fourth, while there are various instruments available 
to measure health-related quality of life, we administered 
the EQ-5D.32 We acknowledge that there may have been 
a potential value in using more than one measure in the 
trial, such as the Short Form Health Survey (SF-36) and 
the Impact of Weight on Quality of Life-Lite to measure 
differences in the positive short-term psychological 
effects.33 However, given the small difference between 
the two groups, it is highly unlikely alternative measures 
would have produced significant differences. Finally, we 
were unable to access Hospital Episode Statistics (HES) 
data containing detailed secondary care resource use 
of NHS services by patients. Obtaining HES data would 
have been problematic as these data would need to 
be linked to HES data by patient ID. Given the short 
time frame of this trial, this was not feasible.34 Where data 
were available for secondary care and missing (inpatient 
admissions, A&E visits, outpatient clinic and other outpa-
tient services), this was accounted for using multiple 
imputation, assuming these data were missing at random. 
It is important to note that when using such methods 
there is uncertainty around the non-observed value across 
the imputations. To account for the uncertainty around 
the values, we employed the non-parametric bootstrap 
approach to estimate the variance (a representation of 
uncertainty) around the true values.23 We acknowledge 
that although multiple imputation is able to statistically 
test for error, this method can produce bias. The bias 
arises from the assumption that missing data in the study 
were ‘missing at random’. For example, the missing at 
random assumption may be reasonable if a variable that 
is predictive of missing data is included in the imputation 
model, but not if the variable is omitted from the model.35 
However, multiple imputation offers an advantage over 
complete case analysis, by filling in missing values and 
enabling participants to be included in the analysis, 
where there were auxiliary variables that are strong 
predictors of missingness.36 Guidelines were followed to 
ensure the model predicted the best possible estimates: 
investigation of the proportion of missing data; selection 
of specific variables; and identification of the predictors 
of missingness.37 We acknowledge that as the percentage 
of missingness increases (in some cases more than 50%), 
there will be greater inefficiency in the imputed data and 
more chance of bias. However, in general the application 
of regression imputation with large missing data may be 
acceptable if adjustments are made for the predictions, as 
we have done.23
In conclusion, the 10TT trial found that after 3 months 
participants receiving 10TT lost significantly more 
weight than those receiving usual care, but there was no 
difference in weight change between the two groups at 
24 months. Similarly, there was no significant difference 
in costs and QALYs between the two arms at 24 months. 
There is no evidence to either recommend or advise 
against 10TT, based on cost-effectiveness considerations.
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